• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024

Opinion
Video

Dr. Mikhael discusses treatment in early relapse of multiple myeloma.

Video content above is prompted by the following question:

  • Please discuss recent updates presented at EHA 2024 in early-relapse multiple myeloma from CARTITUDE-4, KARMMA-2, DREAMM-7, and DREAMM-8.
Related Videos
Mansi Shah, MD
4 experts in this video
4 experts in this video
Dr Xavier Leleu
Dr Xavier Leleu
Francesco Sparano, MSc
Dr Sundar Jagannath
4 experts in this video
Related Content
Westin Forrestal Princeton | Image: Westin

Value-Based Care Calls for Putting Novel Therapies Closer to Patients

June 19th 2025
Article

Coverage from IVBM Princeton, held May 8, 2025.

Read More

Mansi Shah, MD

Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025
Article

Mansi Shah, MD, discusses the role of stem cell transplant in multiple myeloma (MM) and the logistical barriers to wider adoption of bispecific therapies.

Read More

The investigators said real-world use of allo-SCT appeared to be receding as a preferred option after relapse, even before these new data. | Image credit: ibreakstock - stock.adobe.com

Auto-SCT Superior to Allo-SCT in Relapsed Myeloma After First-Line Auto-SCT

June 7th 2025
Article

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line autologous stem cell transplant (auto-SCT).

Read More

IVBM Phoenix logo | Image: AJMC

Translating Best Practices and Ensuring Equitable Care as the Treatment Landscape Evolves

May 19th 2025
Article

Read More

AJMC Q&A with Harsh Parmar, MD | Background image credit: ipopba - stock.adobe.com

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

May 17th 2025
Article

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

Read More

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com

Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

April 25th 2025
Article

When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.

Read More

© 2025 MJH Life Sciences
AJMC®
All rights reserved.